Erika Jones - Jan 30, 2025 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role
Officer Title: Senior Vice President, Finance and Corporate Controller
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Stock symbol
BDTX
Transactions as of
Jan 30, 2025
Transactions value $
$0
Form type
4
Date filed
1/31/2025, 04:35 PM
Previous filing
Feb 15, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDTX Stock Option (Right to Buy) Award $0 +125K $0.00 125K Jan 30, 2025 Common Stock 125K $2.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Officer Title: Senior Vice President, Finance and Corporate Controller